GSK Arexvy protects from RSV over 3 full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...
GSK's Arexvy RSV vaccine demonstrated 43.3% effectiveness in preventing severe illness in its third trial season, following 94.1% effectiveness initially and 64.2% in the second year. The vaccine, one ...
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus ...
GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback